Dieckmann Andreas, Hagedorn Peter H, Burki Yvonne, Brügmann Christine, Berrera Marco, Ebeling Martin, Singer Thomas, Schuler Franz
Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, 2970 Hørsholm, Denmark.
Mol Ther Nucleic Acids. 2018 Mar 2;10:45-54. doi: 10.1016/j.omtn.2017.11.004. Epub 2017 Nov 14.
The successful development of high-affinity gapmer antisense oligonucleotide (ASO) therapeutics containing locked nucleic acid (LNA) or constrained ethyl (cEt) substitutions has been hampered by the risk of hepatotoxicity. Here, we present an in vitro approach using transfected mouse fibroblasts to predict the potential hepatic liabilities of LNA-modified ASOs (LNA-ASOs), validated by assessing 236 different LNA-ASOs with known hepatotoxic potential. This in vitro assay accurately reflects in vivo findings and relates hepatotoxicity to RNase H1 activity, off-target RNA downregulation, and LNA-ASO-binding affinity. We further demonstrate that the hybridization-dependent toxic potential of LNA-ASOs is also evident in different cell types from different species, which indicates probable translatability of the in vitro results to humans. Additionally, we show that the melting temperature (T) of LNA-ASOs maintained below a threshold level of about 55°C greatly diminished the hepatotoxic potential. In summary, we have established a sensitive in vitro screening approach for assessing the hybridization-dependent toxic potential of LNA-ASOs, enabling prioritization of candidate molecules in drug discovery and early development.
含有锁核酸(LNA)或约束乙基(cEt)取代的高亲和力gapmer反义寡核苷酸(ASO)疗法的成功开发受到肝毒性风险的阻碍。在此,我们提出一种体外方法,使用转染的小鼠成纤维细胞来预测LNA修饰的ASO(LNA-ASO)的潜在肝脏不良反应,并通过评估236种具有已知肝毒性潜力的不同LNA-ASO进行验证。这种体外测定法准确反映了体内研究结果,并将肝毒性与RNase H1活性、脱靶RNA下调以及LNA-ASO结合亲和力联系起来。我们进一步证明,LNA-ASO的杂交依赖性毒性潜力在来自不同物种的不同细胞类型中也很明显,这表明体外结果可能适用于人类。此外,我们表明,将LNA-ASO的解链温度(T)维持在约55°C的阈值水平以下可大大降低肝毒性潜力。总之,我们建立了一种灵敏的体外筛选方法,用于评估LNA-ASO的杂交依赖性毒性潜力,从而能够在药物发现和早期开发中对候选分子进行优先排序。